Search

Your search keyword '"Delforge, Michel"' showing total 47 results
Start Over Author "Delforge, Michel" Topic επιστημεσ υγειασ
47 results on '"Delforge, Michel"'

2. Insights on multiple myeloma treatment strategies

Author

Mateos, Mara-Victoria Ludwig, Heinz Bazarbachi, Ali Beksac, Meral Bladé, Joan Boccadoro, Mario Cavo, Michele Delforge, Michel Dimopoulos, Meletios A Facon, Thierry others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2019

3. Phase 2b results of the STORM study: oral selinexor plus low dose dexamethasone (SD) in patients with penta-refractory myeloma (Penta-MM)

Author

Jagannath, Sundar Vogl, Dan T. Dimopoulos, Meletios-Athanasios and Nooka, Ajay Huff, Carol Moreau, Philippe Cole, Craig and Richter, Josh Dingli, David Vij, Ravi Tuchman, Sascha and Raab, Marc-Steffen Weisel, Katja Delforge, Michel and Kaminetzky, David Cornell, Robert Frank Stewart, A. Keith and Hoffman, James Godby, Kelly N. Parker, Terri Lynn Levy, Moshe Schreder, Martin Meuleman, Nathalie Frenzel, Laurent and Mohty, Mohmad Choquet, Sylvain Yee, Andrew and Gavriatopoulou, Maria Costa, Luciano Shah, Jatin and Picklesimer, Carla Saint-Martin, Jean-Richard Li, Lingling and Kauffman, Michael Shacham, Sharon Richardson, Paul Chari, Ajai

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2018

10. Final analysis of overall survival from the first trial

Author

Facon, Thierry Dimopoulos, Meletios A. Dispenzieri, Angela and Catalano, John V. Belch, Andrew Cavo, Michele Pinto, Antonello Weisel, Katja Ludwig, Heinz Bahlis, Nizar J. and Banos, Anne Tiab, Mourad Delforge, Michel Cavenagh, Jamie D. and Geraldes, Catarina Lee, Je-Jung Chen, Christine Oriol, Albert De La Rubia, Javier White, Darrell Binder, Daniel and Lu, Jin Anderson, Kenneth C. Moreau, Philippe Attal, Michel and Fermand, Jean-Paul Avet-Loiseau, Herve Ervin-Haynes, Annette and Chen, Guang Houck, Vanessa Hulin, Cyrille Benboubker, Lofti

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2016

26. European perspective on multiple myeloma treatment strategies in 2014

Author

Ludwig, Heinz Sonneveld, Pieter Davies, Faith Bladé, Joan Boccadoro, Mario Cavo, Michele Morgan, Gareth de la Rubia, Javier Delforge, Michel Dimopoulos, Meletios others

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on “fitness,” with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two-and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results. The Oncologist 2014; 19: 829-844

Published
2014

27. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Author

Dimopoulos, Meletios A. Delforge, Michel Hajek, Roman and Kropff, Martin Petrucci, Maria T. Lewis, Philip Nixon, Annabel Zhang, Jingshan Mei, Jay Palumbo, Antonio

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and at treatment end. Health-related quality of life improved in all treatment groups during induction therapy. Patients receiving lenalidomide maintenance had the most pronounced improvements, Global Health Status/Quality of Life (P

Published
2013

32. Continuous lenalidomide treatment for newly diagnosed multiple myeloma

Author

Palumbo, Antonio Hajek, Roman Delforge, Michel Kropff, Martin Petrucci, Maria Teresa Catalano, John Gisslinger, Heinz Wiktor-Jedrzejczak, Wiesaw Zodelava, Mamia Weisel, Katja others

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Background Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan-prednisone-lenalidomide (MPR) or melphalan-prednisone (MP) followed by placebo in patients 65 years of age or older with newly diagnosed multiple myeloma. Methods We randomly assigned patients who were ineligible for transplantation to receive MPR-R (nine 4-week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progression occurred [152 patients]) or to receive MPR (153 patients) or MP (154 patients) without maintenance therapy. The primary end point was progression-free survival. Results The median follow-up period was 30 months. The median progression-free survival was significantly longer with MPR-R (31 months) than with MPR (14 months; hazard ratio, 0.49; P

Published
2012

33. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Author

Ludwig, Heinz Beksac, Meral Blade, Joan Cavenagh, Jamie and Cavo, Michele Delforge, Michel Dimopoulos, Meletios Drach, Johannes Einsele, Hermann Facon, Thierry Goldschmidt, Hartmut Harousseau, Jean-Luc Hess, Urs Kropff, Martin da Costa, Fernando Leal Louw, Vernon Magen-Nativ, Hila and Mendeleeva, Larisa Nahi, Hareth Plesner, Torben San-Miguel, Jesus Sonneveld, Pieter Udvardy, Miklos Sondergeld, Pia and Palumbo, Antonio

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results